Free Trial
NASDAQ:SNPX

Synaptogenix 5/15/2024 Earnings Report

Synaptogenix logo
$2.40 -0.02 (-0.62%)
As of 12:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Synaptogenix EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Synaptogenix's next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

Synaptogenix Earnings Headlines

Synaptogenix Inc Ordinary Shares
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Synaptogenix Announces $5.0 Million Financing
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:SNPX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

View Synaptogenix Profile

More Earnings Resources from MarketBeat